Latest News
LENZ Therapeutics advances VIZZ regulatory expansion with UK submission for presbyopia treatment
20 April 2026 - US pharmaceutical company LENZ Therapeutics Inc (Nasdaq:LENZ) announced on Monday that it has submitted a marketing authorisation application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA...
GSK secures China approval for Blenrep in relapsed multiple myeloma
20 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received approval from China's National Medical Products Administration for Blenrep (belantamab mafodotin) in combination with bortezomib and...
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically significant lower systemic reactogenicity compared to...
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
20 April 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III MIRANDA trial, demonstrating that its IL-33-targeting biologic, tozorakimab, achieved a stat...
TheraCryf advances Ox-1 programme to clinical stage following successful GMP manufacture
20 April 2026 - TheraCryf plc (AIM: TCF), a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, revealed on Monday that it has completed the Good Manufacturing Practice (GMP) production of over 2kg of cl...